SEC Filings
Crescent Biopharma Has $289.4 Million To Back Cancer Trials Into 2028, It Expects
Patient dosing has begun for CR-002, with initial results expected in the second half of 2027.
SEC Filings
Patient dosing has begun for CR-002, with initial results expected in the second half of 2027.
SEC Filings
The largest bond series initially pays 5.732%, before switching to a floating rate in November 2033.
SEC Filings
Conditional access to more loans could fund operations into 2029, while commercial preparations add to administrative spending.
SEC Filings
The heart-drug developer expects initial human trial results in 2027 as research and administrative costs rise.
SEC Filings
Sempra received $4.56 billion at closing and retained a minority stake, with additional payments due under interest-bearing instruments.
SEC Filings
The cancer-drug developer also moved its executive offices to South San Francisco as it prepares for possible palazestrant commercialization.
SEC Filings
Grimes will join Target's audit, risk and finance oversight as the retailer sharpens its merchandising strategy.
SEC Filings
The stormwater storage purchase expands ADS’s product range as softer demand and transportation costs pressure its existing business.
SEC Filings
Antony F. Spring joined the board in August; his committee appointments took effect immediately on Tuesday.
SEC Filings
The exchange canceled matching Class B shares; reported ownership percentages also count shares available through future unit exchanges.
SEC Filings
The casino landlord fixed the loan's effective rate at approximately 5.20% and lowered pricing on its revolving credit line.
SEC Filings
The investment adviser reported 7,391,329 shares, with shared voting power covering 6,753,733 shares.